AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05447819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplsaty
Description: Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
Study NCT05447819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse shoulder arthroplsaty
Description: Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
Study NCT05924815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet
Study NCT05924815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aficamten-matching Placebo
Description: Oral Tablet
Study NCT05924815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral Tablet
Study NCT05283135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
Study NCT06424106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: a variable rate glucagon infusion
Study NCT06424106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: a variable rate glucose infusion
Study NCT06434220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Baseline model
Description: Model prediction of patient disposition including feature importance scores driving prediction.
Study NCT06434220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fairness-aware model
Description: Model prediction of patient disposition including feature importance scores driving prediction. This model has been tuned to minimize subgroup calibration errors.
Study NCT05108077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytokine-induced killer cells
Description: Autologous cytokine-induced killer cells injected intravenously
Study NCT05108077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder/renal cancer according to the Clinical protocols
Study NCT05108077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder/renal cancer according to the Clinical protocols
Study NCT05587829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: • Diaphragmatic breathing technique
Description: In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
Study NCT05587829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic breathing technique
Description: Deep Breathing for 15 minutes
Study NCT05688033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
Description: dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
Study NCT06519344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD20/CD30-CAR-T Cells
Description: Before cell infusion,researchers may decide, based on necessity, whether to administer prophylactic medication,which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after anti-CD20/CD30-CAR-T cell infusion,including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesice,etc.
Study NCT05481528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Single oral dose of 400 mg moxifloxacin
Study NCT05481528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant
Study NCT05481528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo
Study NCT06074471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided supraclavicular brachial plexus block
Description: Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))
Study NCT06074471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided supraclavicular brachial plexus block
Description: Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))
Study NCT04316390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: study drink (two weeks)
Study NCT04316390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: study drink + Hesperidin 600 mg (two weeks)
Study NCT04316390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: study drink + Vitamin C 250 mg (two weeks)
Study NCT04316390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin + Vitamin C
Description: study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
Study NCT06291675 — intervention group
Intervention type: DRUG
Intervention: gender-affirming hormone therapy
Description: We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
Study NCT06356727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermodilution based assessment of coronary microcirculation
Description: Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
Study NCT05129475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
Study NCT05129475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
Study NCT05177926 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: antiviral prophylaxis with Tenofovir Alafenamide Fumarate
Description: All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
Study NCT04831697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Caregiving Intervention
Description: The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.
Study NCT04831697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Enhanced Usual Care Intervention
Description: This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
Study NCT05170100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NUIG OAB App
Description: An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
Study NCT05025384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation.
Study NCT05087966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention with Navigation Services
Description: A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
Study NCT06195631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle
Description: The SCOPE-E bundle is a multicomponent intervention designed to improve endoscopy ergonomics. The bundle is composed of one core intervention and 5 evidence-based implementation strategies which are defined as methods to enhance the adoption, implementation and sustainment of the core intervention. The core intervention is a pre-endoscopy ergonomic time-out checklist. The implementation strategies are endoscopist education, checklist documentation, visual reminders, nursing engagement and leadership support.
Study NCT05120531 — intervention group
Intervention type: OTHER
Intervention: Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia
Description: Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
Study NCT05980923 — intervention group
Intervention type: OTHER
Intervention: Performing blood thyroid test (TSH, FT4, FT3)
Description: Blood test as above
Study NCT05929196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In vitro full blood diagnostic test.
Description: Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
Study NCT05571644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI + Cadonilimab
Description: Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Study NCT05571644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
Study NCT05571644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Study NCT05716256 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ulinastatin
Description: The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
Study NCT05716256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
Study NCT05716256 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: TOF monitoring
Description: The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
Study NCT05716256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOF monitoring
Description: The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
Study NCT05498077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body scan meditation
Description: Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
Study NCT05195450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate
Description: • TAF 25 mg OD vs no treatment x 5 years and beyond
Study NCT06074809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Guizhi Fuling granules
Description: Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
Study NCT06074809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
Study NCT04939012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPath Intervention
Description: MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.
Study NCT04939012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard of Care
Study NCT04828265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Single dose of aldafermin
Study NCT06080880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron every 3 weeks
Description: Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
Study NCT06080880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant, Po, 125mg/d, 1day' application every 3 weeks
Study NCT05648318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution
Description: In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
Study NCT05648318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
Study NCT06080880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
Study NCT06080880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron weekly
Description: Ondansetron, Po, 24mg/d, 3 days' application weekly
Study NCT05288894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
Study NCT05124834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, blood glucose monitor for personal use
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
Study NCT05124834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, laboratory reference device
Description: measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
Study NCT06435780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIPRF
Description: Denuded interpositional pedicled rolled flap technique
Study NCT06435780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIPRF
Description: Denuded interpositional pedicled rolled flap technique
Study NCT05236413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same.